VERTEX PHARMACEUTICALS INC / MA Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $289.80 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2023-08-02
- VERTEX PHARMACEUTICALS INC / MA proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-06-30 was $239.80M, a 112.97% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-03-31 was $50.00M, a 61.45% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-09-30 was $193.60M, a 16.12% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-06-30 was $112.60M, a 9.11% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $499.30M, a 34.11% increase from fiscal 2020.
- VERTEX PHARMACEUTICALS INC / MA proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2020 was $372.30M, a 21.77% decline from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2019 was $475.90M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|---|---|---|
| 2023-06-30 | $239.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $289.80M 10-Q · filed 2023-08-02 | |||||
| 2023-03-31 | $50.00M 10-Q · filed 2023-05-02 | ||||||
| 2022-09-30 | $193.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $306.20M derived: sum of 2 quarters · filed 2023-08-02 | $435.90M 10-Q · filed 2022-10-28 | $483.10M derived: sum of 4 quarters · filed 2023-08-02 | |||
| 2022-06-30 | $112.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $242.30M 10-Q · filed 2023-08-02 | $289.50M derived: sum of 3 quarters · filed 2023-08-02 | $520.30M derived: sum of 4 quarters · filed 2023-08-02 | |||
| 2022-03-31 | $129.70M 10-Q · filed 2023-05-02 | $176.90M derived: sum of 2 quarters · filed 2023-05-02 | $407.70M derived: sum of 3 quarters · filed 2023-05-02 | $510.90M derived: sum of 4 quarters · filed 2023-05-02 | |||
| 2021-12-31 | $47.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $278.00M derived: sum of 2 quarters · filed 2022-10-28 | $381.20M derived: sum of 3 quarters · filed 2022-10-28 | $499.30M 10-K · filed 2022-02-09 | |||
| 2021-09-30 | $230.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $334.00M derived: sum of 2 quarters · filed 2022-10-28 | $452.10M 10-Q · filed 2022-10-28 | $452.13M 10-Q · filed 2021-11-03 | $639.98M derived: sum of 4 quarters · filed 2022-10-28 | ||
| 2021-06-30 | $103.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $221.30M 10-Q · filed 2022-08-05 | $221.27M 10-Q · filed 2021-07-30 | $409.18M derived: sum of 3 quarters · filed 2022-08-05 | $448.20M derived: sum of 4 quarters · filed 2022-08-05 | ||
| 2021-03-31 | $118.10M 10-Q · filed 2022-05-06 | $118.07M 10-Q · filed 2021-04-30 | $305.98M derived: sum of 2 quarters · filed 2022-05-06 | $345.00M derived: sum of 3 quarters · filed 2022-05-06 | $430.25M derived: sum of 4 quarters · filed 2022-05-06 | ||
| 2020-12-31 | $187.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $226.91M derived: sum of 2 quarters · filed 2022-02-09 | $312.15M derived: sum of 3 quarters · filed 2022-02-09 | $372.30M 10-K · filed 2022-02-09 | |||
| 2020-09-30 | $39.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $124.27M derived: sum of 2 quarters · filed 2021-11-03 | $184.42M 10-Q · filed 2021-11-03 | $285.17M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-06-30 | $85.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $145.40M 10-Q · filed 2021-07-30 | $246.15M derived: sum of 3 quarters · filed 2022-02-09 | $392.59M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-03-31 | $60.15M 10-Q · filed 2021-04-30 | $160.90M derived: sum of 2 quarters · filed 2022-02-09 | $307.34M derived: sum of 3 quarters · filed 2022-02-09 | $428.93M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2019-12-31 | $100.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $247.19M derived: sum of 2 quarters · filed 2022-02-09 | $368.78M derived: sum of 3 quarters · filed 2022-02-09 | $475.90M 10-K · filed 2022-02-09 | |||
| 2019-09-30 | $146.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $268.03M derived: sum of 2 quarters · filed 2020-10-30 | $375.14M 10-Q · filed 2020-10-30 | ||||
| 2019-06-30 | $121.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $228.71M 10-Q · filed 2020-07-31 | |||||
| 2019-03-31 | $107.12M 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |